Helus Pharma finished Phase 3 enrolment early, but HLP003’s decisive test is still ahead
Helus Pharma completes APPROACH enrolment as HLP003 heads toward a pivotal Phase 3 depression data readout in the fourth quarter of 2026.
Pharma & Biotech